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Abstract Recently exonic and intronic mutations in the gene for
microtubule-associated protein tau have been discovered in cases
of familial frontotemporal dementia and parkinsonism linked to
chromosome 17 (FTDP-17). Intronic mutations have been shown
to lead to an abnormal preponderance of four-repeat tau
isoforms. The effects of the exonic mutations are unknown. We
report here that the G272V, P301L, V337M and R406W
mutations lead to a marked reduction in the ability of tau to
promote microtubule assembly. This partial loss-of-function may
be the primary effect of the known missense mutations in tau.
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1. Introduction
Microtubule-associated protein tau is the major component
of the ¢lamentous neuro¢brillary lesions of Alzheimer’s dis-
ease and other tauopathies [1]. The mechanisms that lead to
the formation of hyperphosphorylated tau ¢laments in brain
are only poorly understood. Recently, exonic and intronic
mutations in the tau gene have been identi¢ed in familial
‘frontotemporal dementia and parkinsonism linked to chro-
mosome 17’ (FTDP-17) [2^4]. Four separate missense muta-
tions and four separate intronic mutations have been de-
scribed in 13 families with FTDP-17.
In adult human brain, six tau isoforms are produced from a
single gene by alternative mRNA splicing [5]. They di¡er by
the presence or absence of inserts of 29 and 58 amino acids
located in the amino-terminal half and a 31 amino acid repeat
located in the carboxy-terminal half. Inclusion of the latter,
which is encoded by exon 10 of the tau gene [5^7], gives rise to
tau isoforms with four microtubule-binding repeats. Intronic
mutations are located close to the splice-donor site of the
intron following exon 10, where they disrupt a predicted
stem-loop structure [3,4]. This has been shown to lead to in-
creased levels of the three tau isoforms with four microtubule-
binding repeats and to reduced levels of the three isoforms
with three microtubule-binding repeats [3,4]. Overproduction
of four-repeat tau isoforms may lead to an excess of tau over
available binding sites on microtubules [4], resulting in the
assembly of four-repeat isoforms into wide twisted ribbon-
like ¢laments [8]. The known exonic mutations in tau are
located in the microtubule-binding repeat region or close to
it, suggesting that they may interfere with the ability of tau to
interact with microtubules [2,3]. We have therefore examined
the e¡ects of these mutations in the context of a three-repeat
and a four-repeat tau isoform on the promotion of micro-
tubule assembly.
2. Materials and methods
2.1. Expression and puri¢cation of wild-type and mutated tau proteins
Site-directed mutagenesis was used to change G272 to valine, V337
to methionine and R406 to tryptophan in the three-repeat 381 amino
acid isoform of human tau (expressed from cDNA clone htau37) and
in the four-repeat 412 amino acid isoform (expressed from cDNA
clone htau46) (in the numbering of the 441 amino acid isoform of
human tau). P301 was changed to leucine in the four-repeat isoform.
All constructs were veri¢ed by DNA sequencing. Wild-type and mu-
tated tau proteins were expressed in E. coli BL21(DE3), as described
[9]. Bacterial pellets were resuspended in 50 mM PIPES, 1 mM
EGTA, 1 mM DTT, 0.5 mM PMSF, 0.5 Wg/ml leupeptin, pH 6.8,
followed by a 2U1-min sonication on ice using a Kontes Micro Ultra-
sonic Cell Disrupter. The homogenates were centrifuged at 27 000Ug
for 15 min and the supernatants ¢ltered through a 0.45-Wm Acrodisc.
The ¢ltrate was loaded onto a phosphocellulose column (bed volume
2 ml) equilibrated in extraction bu¡er. The column was washed in
extraction bu¡er, followed by extraction bu¡er+0.1 M NaCl. Protein
was eluted batchwise with 6 ml extraction bu¡er containing 0.3 M
NaCl. This was followed by overnight dialysis against a saturated
ammonium sulfate solution and precipitation by a 10-min centrifuga-
tion at 50 000 rpm (Beckman TL100). The pellet was resuspended in
extraction bu¡er and reprecipitated by addition of an equal volume of
saturated ammonium sulfate. Following centrifugation, the pellet was
resuspended in 1 ml extraction bu¡er containing 0.5 M NaCl and 1%
2-mercaptoethanol, and boiled for 3 min. Following a 10-min centrif-
ugation at 50 000 rpm, the supernatant was loaded onto a NAP10
column equilibrated in 80 mM PIPES, 1 mM EGTA, 0.2 mM MgCl2,
1 mM DTT (microtubule assembly bu¡er minus GTP) and eluted
with 1.5 ml of the same bu¡er. GTP was added to 1 mM. Tau protein
concentrations were determined using densitometry (Molecular Dy-
namics) and calibration against tau protein of known concentration.
Bovine serum albumin was used as the standard for densitometry. In
all experiments, wild-type and mutant tau proteins were expressed and
puri¢ed in parallel.
2.2. Microtubule assembly
Four-repeat tau isoforms assemble microtubules at a 2.5^3.0-fold
faster rate than isoforms with three repeats [9]. To obtain similar rates
of assembly, we used a higher concentration of three-repeat than of
four-repeat tau isoforms. Puri¢ed recombinant wild-type and mutated
htau37 (0.3 mg/ml, 6.9 WM) and htau46 (0.1 mg/ml, 2.3 WM) proteins
were incubated with bovine brain tubulin (1 mg/ml, 20 WM, Cyto-
skeleton) in assembly bu¡er at 37‡C, as described [10]. The assembly
of tubulin into microtubules was monitored over time by a change in
turbidity at 350 nm.
3. Results
Tau proteins with mutations showed a reduced ability to
promote microtubule assembly (Figs. 1 and 2). The smallest
e¡ect was observed with the R406W mutant and the largest
e¡ect with the P301L mutant. The V337M and G272V muta-
tions produced intermediate e¡ects. All the mutations had a
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larger e¡ect in three-repeat than in four-repeat tau isoforms.
Thus, the R406W mutation led to a 40% reduction in the rate
of microtubule assembly in the three-repeat tau isoform, but
only to a 20% reduction in the four-repeat isoform (expressed
as the optical density at 2 min). An 85% reduction was found
for the V337M mutation in the three-repeat tau isoform and a
55% reduction in the four-repeat isoform. The G272V muta-
tion produced a 70% reduction in the rate of microtubule
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Fig. 1. E¡ects of missense mutations in tau on the ability of three-
repeat htau37 (381 amino acid isoform of human tau) to promote
microtubule assembly. A: Schematic diagram of wild-type and mu-
tated htau37. The three tandem repeats are shown as black bars,
with the alternatively spliced exon 2 shown as shaded bar. The posi-
tions of the FTDP-17 mutations at residues 272, 337 and 406 are
indicated. B: Polymerisation of tubulin induced by wild-type
htau37, htau37 G272V, htau37 V337M and htau37 R406W, as
monitored over time by turbidimetry. A typical experiment is
shown; similar results were obtained in three separate experiments.
C: Optical densities for wild-type htau37 and the three mutants at
2 min (expressed as % of wild-type htau37, taken as 100%). The re-
sults are expressed as means þ S.E.M. (n = 3). Amino acid numbering
is according to the 441 amino acid isoform of human tau.
Fig. 2. E¡ects of missense mutations in tau on the ability of four-re-
peat htau46 (412 amino acid isoform of human tau) to promote mi-
crotubule assembly. A: Schematic diagram of wild-type and mu-
tated htau46. The four tandem repeats are shown as black bars,
with the alternatively spliced exons 2 and 10 shown as shaded bars.
The positions of the FTDP-17 mutations at residues 272, 301, 337
and 406 are indicated. B: Polymerisation of tubulin induced by
wild-type htau46, htau46 G272V, htau46 P301L, htau46 V337M
and htau46 R406W, as monitored over time by turbidimetry. A typ-
ical experiment is shown; similar results were obtained in three sep-
arate experiments. C: Optical densities for wild-type htau46 and the
four mutants at 2 min (expressed as % of wild-type htau46, taken
as 100%). The results are expressed as means þ S.E.M. (n = 3). Ami-
no acid numbering is according to the 441 amino acid isoform of
human tau.
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assembly in the three-repeat tau isoform and a 60% reduction
in the four-repeat isoform. The P301L mutation, which is only
found in four-repeat tau isoforms, produced a 90% reduction
in the rate of tubulin polymerisation (Fig. 2).
4. Discussion
These ¢ndings demonstrate that missense mutations in tau
which are associated with FTDP-17 lead to a reduction in the
ability of tau protein to promote microtubule assembly, akin
to a partial loss-of-function. Microtubule assembly as meas-
ured in this assay is the product of microtubule nucleation
and growth. Future experiments will separately test the e¡ects
of the tau mutations on microtubule nucleation and growth.
The three-repeat tau isoform was a¡ected more strongly by
the mutations than the four-repeat isoform, indicating a dif-
ferential isoform e¡ect of the G272V, V337M and R406W
mutations. The e¡ects of the G272V and V337M mutations
were stronger than those of the R406W mutation, in keeping
with their location in the microtubule-binding repeat region.
The R406W mutation is located downstream of the repeats.
The P301L mutation produced the largest reduction in the
rate of microtubule assembly. It is located in the alternatively
spliced repeat which gives rise to tau isoforms with four re-
peats. Unlike the G272V, V377M and R406W mutations
which a¡ect all six tau isoforms, the P301L mutation only
a¡ects four-repeat isoforms.
It is well established that the repeat region of tau and some
£anking sequences are required for full biological activity [11].
However, relatively little is known about the exact sequence
requirements. Several positively charged residues have been
shown to have a strong in£uence on the ability of tau to
promote microtubule assembly [12^14], in keeping with evi-
dence indicating that the binding of tau to microtubules is
governed by electrostatic interactions [15]. The present results
show that the sequence requirements in tau for the promotion
of microtubule assembly are not limited to charge interac-
tions, since of the four missense mutations only the R406W
mutation leads to a reduction in positive charge. They are
consistent with ¢ndings showing that the nucleation of micro-
tubules involves steps that are not a¡ected by the binding
of tau to microtubules [16,17] and suggest that the known
exonic mutations in tau may a¡ect the nucleation of micro-
tubules.
The partial loss-of-function resulting from the reduced abil-
ity of mutated tau to promote microtubule assembly is prob-
ably the primary e¡ect of the tau mutations. It may represent
a necessary step for permitting the subsequent hyperphos-
phorylation of tau which, in conjunction with other factors
[10,18^20], is believed to lead to assembly into ¢laments. It
remains to be determined whether the mutations have addi-
tional e¡ects on tau phosphorylation and ¢lament assembly.
Tau mutations in the intron following exon 10 or in exon 10
itself lead to a neuronal and glial pathology [4,21], whereas
mutations located outside exon 10 lead to a predominantly
neuronal tau pathology [21^23]. In normal adult human
brain, tau is predominantly found in nerve cells, with only
low levels in glial cells [6,24^27]. Six tau isoforms are ex-
pressed, with a slight preponderance of three-repeat over
four-repeat isoforms [5,9]. Although it is not known which
tau isoforms are expressed in glial cells, the cellular pathology
of FTDP-17 is compatible with nerve cells expressing all six
tau isoforms and glial cells expressing predominantly four-
repeat isoforms. In the case of mutations located outside
exon 10, the ordered assembly of tau into ¢laments may be
driven by three-repeat isoforms, consistent with the larger
e¡ects of mutated three-repeat tau reported here.
The sequence of events, which leads from a reduced ability
of tau to interact with microtubules to assembly into ¢la-
ments, may also apply to other diseases with a ¢lamentous
tau pathology, such as Alzheimer’s disease, progressive supra-
nuclear palsy, Pick’s disease and corticobasal degeneration.
Thus, the V337M mutation in tau leads to a tau pathology
which is indistinguishable from that of Alzheimer’s disease in
its ultrastructural and biochemical characteristics [2,22]. The
R406W mutation gives rise to a tau pathology with some
characteristics reminiscent of Alzheimer’s disease [3,23]. The
G272V mutation in tau leads to the formation of Pick-like
bodies, whereas the P301L mutation produces a tau pathology
similar to that of corticobasal degeneration and progressive
supranuclear palsy [3,21].
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